Please login to the form below

Not currently logged in
Email:
Password:

cancer immunotherapies

This page shows the latest cancer immunotherapies news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Sutent sales slipped 1% last year to just over $1bn but could suffer as Opdivo and other cancer immunotherapies get approved in front-line RCC, despite Pfizer claiming FDA approval of ... type of cancer - could eventually find broader utility in RCC.

Latest news

  • BMS’ Opdivo plus Yervoy aces phase III trial BMS’ Opdivo plus Yervoy aces phase III trial

    first-line lung cancer patients may benefit most from the combination of Opdivo and Yervoy.”. ... If the combo is approved however, the US pharma firm could be put in a strong position to take on Keytruda, which is already dominating the cancer

  • BMS' Yervoy picks up another indication in Europe BMS' Yervoy picks up another indication in Europe

    BMS' Yervoy picks up another indication in Europe. The EC licenses the immuno-oncology treatment for children with skin cancer. ... However, Merck &Co’s leading position in the cancer immunotherapies market is so far unmatched, with Keytruda picking up

  • Merck chalks up another win for Keytruda in lung cancer Merck chalks up another win for Keytruda in lung cancer

    Merck chalks up another win for Keytruda in lung cancer. Becomes the first PD-1 inhibitor to improve OS in NSCLC patients when combined with chemo. ... Merck &Co’s already dominant position in the market for cancer immunotherapies for first-line lung

  • Pharma is ‘getting lower returns on R&D’ Pharma is ‘getting lower returns on R&D’

    Meanwhile, the pharma industry as a whole has turned its attention to cancer, with oncology projects now accounting for 37% of the total late-stage pipeline, up from 18% in 2010, ... as this year’s approval of CAR-T cancer immunotherapies and the first

  • Lung cancer data gives Roche’s Tecentriq a boost Lung cancer data gives Roche’s Tecentriq a boost

    Lung cancer data gives Roche’ s Tecentriq a boost. Will help its PD-L1 inhibitor compete with Merck &Co’s Keytruda. ... He also said the data lends weight to the approach of combining cancer immunotherapies with chemotherapy, rather than pairing

More from news
Approximately 24 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Back in June 2015 Celgene and Juno announced a ten-year collaboration to combine their respective immunology expertise to develop new immunotherapies for cancer and autoimmune diseases based on T cell ... Tucatinib is currently being evaluated in a phase

  • Deal Watch November 2015 Deal Watch November 2015

    A package deal covering up to five cancer immunotherapies, the headline value was $1.56bn with an upfront fee of $60m; the subsequent milestone terms per product could reach in excess ... Sanofi will gain access to BioNTech's mRNA formulation technology

  • Pharma deals in June 2015 Pharma deals in June 2015

    Immune modulators in cancer and beyond. Both Juno Therapeutics and Celgene have had a busy month in forming alliances in the immunotherapy area. ... Near the close of the month, Juno and Celgene announced a $1bn, 10-year collaboration to develop novel

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    Phase 3 immuno-oncology treatment for prostate cancer. 975. Intrexon / Merck Serono. ... 825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214. ... 525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast / gastric cancer.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Targovax strengthens board of directors Targovax strengthens board of directors

    of our novel and complementary portfolio of cancer immunotherapies.”.

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    He said: “ Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer. ... Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral

  • Merck’s Richard Murray joins Jounce as CEO Merck’s Richard Murray joins Jounce as CEO

    Merck’ s Richard Murray joins Jounce as CEO. He brings experience in cancer immunotherapies to the US biotech. ... pembrolizumab. This experience will benefit Jounce, a Cambridge, Massachusetts-based company that specialises in cancer immunotherapies.

  • Bruno Strigini leaves Merck & Co for Novartis Bruno Strigini leaves Merck & Co for Novartis

    These sales made Novartis the third largest pharma company in cancer for the year. ... The area of anti-PD1 cancer immunotherapies looks to be an important one for many companies, with Bristol-Myers Squibb, Roche and AstraZeneca all developing their own

  • Kite Pharma appoints head of regulatory affairs Kite Pharma appoints head of regulatory affairs

    Dr Sproule is the latest in a string of senior appointments at Kite as the company prepares for the advance of its research projects involving cancer immunotherapies. ... Other recent additions include chief financial officeras chief medical officer; and

More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics